- Fulfilment rates are growing relative to last quarter, and so are prescriptions.
- Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that.
- As a digital company, they are pushing their own dashboard which seems to be picking up traction and creates some leverage potential for economies of scale and scope.
- ASPs are higher than we modeled still but will decline as rebates bring net prices down, but this would be concomitant with larger contracts and a good thing.
- Still early days, so who knows how long it will go, but the current cash position let us see till 2023 before more dilution.
For further details see:
Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction